Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.

Liu Y, Jiang X, Chen X

Lipids in health and disease2 Dec 2017Cited by 25 (Europe PMC)

PMID29197387PMCIDPMC5712174DOI10.1186/s12944-017-0609-0PepBankPUB-29197387

Summary

BackgroundThis study is to compare the effects of Liraglutide and Metformin alone or combined treatment on the cardiac function in T2DM patients complicated with CAD.Methods120 T2DM patients were included at Endocrinology Department of Tianjin First Center Hospital (Tianjin, China) from April 2012 to September 2013. The study contained two sections. Section 1: 30 patients in group 1 was treated with Liraglutide (Novo Nordisk) (1.2 mg/d), and 30 patients in group 2 with Metformin (Shiguibao) (1500 mg/d) for 24 weeks. Section 2: 30 patients in group1 was treated with Liraglutide (1.8 mg/d) and 30 in group 2 with Liraglutide (1.2 mg/d) plus Metformin (1500 mg/d) for 24 weeks. Fasting blood glucose (FBG), postprandial glucose (PPG), glycated hemoglobin (HbA1c), body mass index (BMI), blood pressure (BP), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), C reactive protein (CRP), left ventricular end-diastolic diameter (LVEDD), ejection fraction (EF) and the ratio of early (E) to late (A) ventricular filling velocities (E/A ratio) were measured before and after the 24-week treatment.ResultsAfter 24-week treatment, when blood glucose level was controlled in 4 groups, Liraglutide alone treatment showed better improvements than on all measuring except TG in Section 1, however, combined treatment of Liraglutide and Metformin showed better improvements on all measuring except BMI, TG and BP in Section 2.ConclusionsWith similar glycemic control, the Liraglutide (1.2 mg/d) monotherapy showed the better effects than either Metformin alone, or combination of Liraglutide and Metformin on lipid metabolism and cardiovascular function.Trial registrationThis trial was registered at Chinese Clinical Trial Registry ( chictr.org.cn ) # ChiCTR-IPR-16008578 .

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

01HumanObservational studyEfficacy outcome
In patients with type 2 diabetes and coronary artery disease, liraglutide alone improved all measures except triglycerides more than metformin alone.
In plain wordsIn people with type 2 diabetes and heart disease, liraglutide alone improved most measures more than metformin alone, but not triglycerides.
Peptide
Liraglutide
Outcome
MixedGlycemic, lipid, blood pressure and cardiac measures
Study
n = 60
Comparator
Metformin 1500 mg/d
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
1.2 mg/d · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide alone treatment showed better improvements than on all measuring except TG in Section 1
2 context sentences(design, population, supporting numbers)
Summary · context
120 T2DM patients were included at Endocrinology Department of Tianjin First Center Hospital (Tianjin, China) from April 2012 to September 2013.
Summary · context
were measured before and after the 24-week treatment.
Show in the study text Report a problemFND-2919738701

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with type 2 diabetes and coronary artery disease, liraglutide 1.2 mg/d plus metformin improved all measures except BMI, triglycerides and blood pressure more than liraglutide 1.8 mg/d.
In plain wordsIn people with type 2 diabetes and heart disease, liraglutide plus metformin improved most measures more than a higher liraglutide dose alone.
Peptide
Liraglutide
Outcome
MixedGlycemic, lipid, blood pressure and cardiac measures
Study
n = 60
Comparator
Liraglutide 1.8 mg/d
Outcome group
Cardiometabolic risk factors · Cardiovascular
Source sentences
Summary
combined treatment of Liraglutide and Metformin showed better improvements on all measuring except BMI, TG and BP in Section 2.
2 context sentences(design, population, supporting numbers)
Summary · context
120 T2DM patients were included at Endocrinology Department of Tianjin First Center Hospital (Tianjin, China) from April 2012 to September 2013.
Summary · context
were measured before and after the 24-week treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2919738702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.